Log In
BCIQ
Print this Print this
 

GM102 (formerly 3C23K)

  Manage Alerts
Collapse Summary General Information
Company LFB S.A.
Description mAb targeting anti-Mullerian hormone receptor type II (AMHR2)
Molecular Target Anti-Mullerian hormone receptor type II (AMHR2)
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase I
Standard IndicationOvarian cancer
Indication DetailsTreat advanced, previously treated gynecological cancers; Treat ovarian cancer
Regulatory Designation
PartnerGamaMabs Pharma S.A.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

2

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

12/16/2014

Undisclosed

Undisclosed

Undisclosed

10/07/2013

Undisclosed

0

0

Get a free BioCentury trial today